Clinical and pathological characteristics of HIV- and HHV-8–negative Castleman disease

Authors: Yu Li, Meifeng Tu, Jörge E. Cortes, Zijun Y. Xu‐Monette, Roberto N. Miranda, Jun Zhang, Robert Z. Orlowski, Sattva S. Neelapu, Prajwal Boddu, Mary Akosile, Thomas S. Uldrick, Robert Yarchoan, L. Jeffrey Medeiros, Yong Li, David C. Fajgenbaum, Ken H. Young - Blood 2017 cited by 179

cells, 17.37 ± 15.80). Complete surgical resection is a better option for patients with UCD. Siltuximab had a greater proportion of complete responses and longer progression-free survival (PFS) for iMCD than rituximab. Centricity, histopathological type, and anemia significantly impacted PFS. This study reveals that CD represents a heterogeneous group of diseases with differential immunophenotypic profiling and treatment response.